New drug FS1502 targets Hard-to-Treat HER2 cancers in early trial

NCT ID NCT03944499

Completed Disease control Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called FS1502 in 161 people with advanced solid tumors or breast cancer that express HER2. The study had two parts: first, finding a safe dose, and then seeing how well that dose works. The goal was to check safety and early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FS-1502 (an experimental drug given by IV)
What this could lead to: If it works, this could point toward a new treatment option for people with HER2-positive advanced solid tumors or breast cancer.
What could go wrong: This is a very early Phase 1 trial with only 161 participants, so safety and dosing are still being figured out. It may not show strong anti-tumor effects or lead to a widely available therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China
Henan Cancer Hospital

Zhengzhou, Henan, China
Jilin Cancer Hospital

Jilin City, Changchun, China
Meizhou People's Hospital

Meizhou, Guangdong, China
Run Run Shaw Hospital Affiliated to Medical College of Zhejiang University

Hangzhou, Zhejiang, 310016, China
Shandong Cancer Hospital

Jinan, Shandong, China
Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences

Shenzhen, Guangdong, 518000, China
Sun Yat-sen University Cancer Prevention Center

Guangzhou, Guangdong, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050011, China
Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.